Society of Hematologic Oncology's Annual Meeting

In this article, Michael Bloch, MD, and Evan Bloch discuss findings from the SELECT trial, including the use of the glucagon-like peptide 1 receptor agonist, semaglutide, to reduce the risk of major...

In this article, Michael J. Bloch, MD, writes about the results of the recently published BrightHTN study, which examined the use of the investigational aldosterone synthase inhibitor baxdrostat in patients...

In this article, Michael J. Bloch, MD, writes about the results of the recently published BrightHTN study, which examined the use of the investigational aldosterone synthase inhibitor baxdrostat in patients...

In this article, Michael J. Bloch, MD, writes about the results of the recently published BrightHTN study, which examined the use of the investigational aldosterone synthase inhibitor baxdrostat in patients...

In this article, Michael J. Bloch, MD, writes about the results of the recently published BrightHTN study, which examined the use of the investigational aldosterone synthase inhibitor baxdrostat in patients...

Consultant is excited to introduce two new content offerings that will be regular features in our monthly eTOC: Case Report Insights and Photoclinic Challenges.

In this article, Michael J. Bloch, MD, and Evan Bloch discuss the findings from the CARDIA-SSBP trial, which investigates the blood pressure responses to dietary sodium increase and decrease across a wide...

In this article, Michael J. Bloch, MD, and Evan Bloch discuss the findings from the CARDIA-SSBP trial, which investigates the blood pressure responses to dietary sodium increase and decrease across a wide...

In this article, Michael J. Bloch, MD, and Evan Bloch discuss the findings from the CARDIA-SSBP trial, which investigates the blood pressure responses to dietary sodium increase and decrease across a wide...

Consultant360 thanks each of our peer reviewers for their time and expertise.